CLRB logo

CELLECTAR BIOSCIENCES INC

CLRBNASDAQ
πŸ† #4840 by market capEarnings Mar 3US Equity
$0.80β–Ό $0.09 (βˆ’9.73%)
Market closed Β· at close
πŸ””
Track CLRB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 9.7%
7dβ–Ό 29.8%
14dβ–Ό 37.2%
30dβ–Ό 33.6%
ytdβ–Ό 72.5%
1yβ–Ό 72.6%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.78 – $0.90
52-Week Range
$0.76 – $4.70
Volume (shares)
81,067
Avg Volume (shares)
β€”
Shares Outstanding
10.0M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.2
P/S Ratio
0.0x
EPS (TTM)
$-1.48
Dividend Yield
0.00%
Dilution (1yr)
+203.3%
CLRB logo

CELLECTAR BIOSCIENCES INC

CLRB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$23Mβ–Ό βˆ’55.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$23Mβ–Ό βˆ’51.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.2Mβ–² +203.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13Mβ–Ό βˆ’$10M YoY
StockOtter Β· stockotter.space

About CELLECTAR BIOSCIENCES INC

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

Seeking AlphaΒ·11d ago

Cellectar Biosciences, Inc. (CLRB) Q3 2026 Earnings Call Transcript

Cellectar Biosciences, Inc. ( CLRB ) Q3 2026 Earnings Call November 10, 2026 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Of

GlobeNewsWireΒ·12d ago

Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Presented updated data at the International Workshop for WaldenstrΓΆm Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in WaldenstrΓΆm macroglobulinemia (WM)

GlobeNewsWireΒ·18d ago

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in WaldenstrΓΆm Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition

Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site a

GlobeNewsWireΒ·20d ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026

FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of can

GlobeNewsWireΒ·26d ago

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

Durable Complete Response Achieved with Single Administration of Iopofosine I 131Β  Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Ra

GlobeNewsWireΒ·Oct 15

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for WaldenstrΓΆm Macroglobulinemia

Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months